Affinage

TAGLN2

Transgelin-2 · UniProt P37802

Length
199 aa
Mass
22.4 kDa
Annotated
2026-04-28
50 papers in source corpus 22 papers cited in narrative 22 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TAGLN2 is an actin-binding protein that controls cytoskeletal dynamics in immune cells, endothelial cells, and epithelial contexts by stabilizing F-actin through competition with cofilin, inhibiting Arp2/3-mediated branched actin nucleation, and nucleating linear actin polymerization via its calponin homology domain (PMID:25869671, PMID:29615809). In T cells, TAGLN2 is essential for immunological synapse formation, LFA-1 activation, cytokine production, and cytotoxic effector function, while in macrophages it is NF-κB-induced and required for phagocytosis of opsonized particles and bacterial clearance in vivo (PMID:25869671, PMID:28821818, PMID:30524895). PFTK1-mediated phosphorylation at S83 and S163 attenuates TAGLN2 actin-binding activity and relieves its suppression of cell motility, and succinylation at K40 modulates its interaction with TMSB4X to promote angiogenesis and glioma progression (PMID:21577206, PMID:36131066). In diverse tumor contexts, TAGLN2 drives invasion and therapy resistance through ERK1/2–MGMT, ANXA2–STAT3, Rap1–PI3K–AKT, and AKT–YBX1–cGAS-STING signaling axes, and tumor-derived exosomal TAGLN2 promotes angiogenesis via a NRP1–SEMA4D–YAP ternary complex (PMID:38992489, PMID:34466149, PMID:36222755, PMID:39168971, PMID:41824788).

Mechanistic history

Synthesis pass · year-by-year structured walk · 13 steps
  1. 2011 High

    PFTK1-mediated phosphorylation at S83/S163 was identified as a mechanism that attenuates TAGLN2 actin-binding activity, establishing that post-translational modification directly regulates the cytoskeletal suppressor function of TAGLN2 and linking it to tumor cell motility control.

    Evidence 2D-PAGE/MS phosphosubstrate identification, site-directed mutagenesis, actin-binding assays, and genetic epistasis in HCC cells

    PMID:21577206

    Open questions at the time
    • Kinases other than PFTK1 that phosphorylate these sites are uncharacterized
    • Structural basis for how S83/S163 phosphorylation disrupts actin binding is unresolved
  2. 2011 Medium

    TAGLN2 was established as a direct target of miR-1 and miR-133a, with functional knockdown showing that TAGLN2 promotes proliferation and suppresses apoptosis in cancer cells, providing the first post-transcriptional regulatory axis for TAGLN2.

    Evidence Luciferase 3′-UTR reporter assays and siRNA knockdown in bladder and head-and-neck squamous cell carcinoma lines

    PMID:21304530 PMID:21378409

    Open questions at the time
    • How miR-1/miR-133a regulation of TAGLN2 integrates with its actin-binding function was not addressed
    • In vivo confirmation of miRNA-mediated TAGLN2 regulation is lacking
  3. 2015 High

    Knockout studies resolved a long-standing question about how T cells maintain F-actin at the immunological synapse: TAGLN2 stabilizes cortical F-actin by competing with cofilin and is required for LFA-1 activation, cytokine secretion, and cytotoxic function.

    Evidence TAGLN2-knockout mice, in vitro cofilin competition assays, live imaging, and cytokine/granzyme B functional assays

    PMID:25869671

    Open questions at the time
    • Whether TAGLN2 directly binds LFA-1 or acts through an intermediate remains incompletely defined
    • Regulation of TAGLN2 expression or activity during TCR signaling is not established
  4. 2017 High

    TAGLN2 was shown to be essential for macrophage phagocytosis and in vivo antibacterial defense, with NF-κB identified as the transcriptional inducer downstream of LPS, broadening TAGLN2's immune function beyond T cells.

    Evidence TAGLN2-knockout mice, phagocytosis of opsonized particles, NF-κB pathway inhibition, and in vivo bacterial infection survival

    PMID:28821818

    Open questions at the time
    • The precise actin-remodeling step TAGLN2 controls during phagosome formation is undefined
    • Whether TAGLN2 acts identically in other myeloid cell types is untested
  5. 2018 High

    Reconstitution experiments defined TAGLN2's dual biochemical activities: G-actin nucleation via the calponin homology domain under low-salt conditions, and inhibition of Arp2/3-mediated branched nucleation under physiological conditions, explaining how TAGLN2 shifts the balance from branched to linear actin networks.

    Evidence In vitro actin polymerization assays with domain mutagenesis and Arp2/3 binding assays, live cell filopodia imaging

    PMID:29615809

    Open questions at the time
    • Whether ionic-strength-dependent nucleation is physiologically relevant inside cells is unclear
    • A high-resolution structural model of the TAGLN2–actin interface is absent
  6. 2018 Medium

    TAGLN2 was shown to associate with LFA-1 and potentiate inside-out costimulation, with exogenous TAGLN2 delivery enhancing CAR-T cell cytotoxicity in vitro and in xenograft models, providing translational proof-of-concept.

    Evidence Co-localization studies, recombinant protein transduction domain fusion, OTI CD8+ T cell killing assays, and xenograft model

    PMID:30524895

    Open questions at the time
    • Biochemical details of the TAGLN2–LFA-1 interaction (direct vs. indirect, binding site) are not defined
    • Long-term safety and efficacy of exogenous TAGLN2 delivery in vivo are unknown
  7. 2021 Medium

    Zebrafish studies placed tagln2 downstream of the transcription factor klf6a in blood-flow-driven vessel pruning, establishing a developmental role in endothelial cell rearrangement and actin remodeling beyond immune cells.

    Evidence Zebrafish klf6a loss-of-function with tagln2 rescue, live imaging of endothelial cell migration and junction remodeling

    PMID:34319989

    Open questions at the time
    • Whether the klf6a-TAGLN2 axis is conserved in mammalian vascular pruning is untested
    • Molecular targets of TAGLN2 in endothelial junction remodeling are unidentified
  8. 2021 Medium

    TAGLN2 was linked to STAT3 activation through ANXA2 in colorectal cancer, establishing ANXA2 as a functional partner through which TAGLN2 promotes EMT and invasion.

    Evidence TAGLN2 knockdown/overexpression with STAT3 inhibitor rescue in CRC cell lines

    PMID:34466149

    Open questions at the time
    • Direct physical interaction between TAGLN2 and ANXA2 was not demonstrated by reciprocal methods
    • Whether TAGLN2-ANXA2 interaction is cytoskeleton-dependent is unknown
  9. 2022 Medium

    Succinylation at K40 was identified as a functionally critical post-translational modification that governs TAGLN2's interaction with TMSB4X and promotes angiogenesis in glioma, adding a second regulatory PTM to the phosphorylation already known.

    Evidence LC-MS/MS succinylation proteomics, succinylation-mimetic and loss-of-function mutagenesis, angiogenesis assays, xenograft model

    PMID:36131066

    Open questions at the time
    • The enzyme(s) catalyzing K40 succinylation are unidentified
    • How K40 succinylation affects TAGLN2's actin-binding or cofilin-competing activities is untested
  10. 2022 Medium

    TAGLN2 was shown to directly bind E-cadherin and regulate its extracellular domain cleavage, controlling trophoblast migration/fusion, while in vivo overexpression induced a preeclampsia-like syndrome—connecting TAGLN2 to placental biology.

    Evidence Co-IP and microscale thermophoresis for direct binding, functional assays in trophoblasts, adenoviral overexpression in pregnant mice

    PMID:35281112

    Open questions at the time
    • The mechanism by which TAGLN2 promotes E-cadherin cleavage (protease recruitment vs. conformational change) is unknown
    • Findings are from a single lab and await independent confirmation
  11. 2024 Medium

    TAGLN2 was found to interact with ERK1/2 and promote its nuclear translocation, upregulating MGMT to confer temozolomide resistance in GBM, while NF-κB was validated as a direct transcriptional activator of TAGLN2 by ChIP-PCR.

    Evidence Co-IP/LC-MS/MS for ERK1/2 interaction, ChIP-PCR for NF-κB at TAGLN2 promoter, intracranial xenograft

    PMID:38992489

    Open questions at the time
    • Whether TAGLN2 acts as a scaffold for ERK1/2 nuclear import or modulates upstream kinase activity is unclear
    • Generalizability of NF-κB–TAGLN2–MGMT axis beyond GBM is untested
  12. 2024 Medium

    TAGLN2 was shown to drive therapy resistance by forming a complex with AKT and YBX1, promoting YBX1 phosphorylation and nuclear translocation, which activates cGAS-STING and upregulates interferon-stimulated genes.

    Evidence Co-IP for TAGLN2-AKT-YBX1, ChIP for c-Myc/SOX9 at YBX1 promoter, cGAS-STING pathway assays, pharmacological disruption with Fisetin/MK2206, xenograft

    PMID:39168971

    Open questions at the time
    • Stoichiometry and structural basis of the TAGLN2-AKT-YBX1 ternary complex are undefined
    • Relationship between TAGLN2's actin-binding and its AKT-YBX1 scaffolding functions is unknown
  13. 2025 Medium

    Exosomal TAGLN2 was found to activate a non-canonical angiogenic pathway by forming a cytoplasmic NRP1-SEMA4D-YAP ternary complex in endothelial cells, establishing an intercellular signaling role for TAGLN2 independent of its intracellular actin-binding function.

    Evidence Exosome isolation, Co-IP for ternary complex, ChIP for c-Jun/SP1 at NRP1 promoter, YAP localization assays, xenograft model

    PMID:41824788

    Open questions at the time
    • How TAGLN2 in exosomes retains bioactivity after uptake is unclear
    • Whether other exosomal cargo cooperates with TAGLN2 in this axis is unknown
    • Findings from a single lab

Open questions

Synthesis pass · forward-looking unresolved questions
  • A unifying structural and regulatory model explaining how TAGLN2's actin-binding, scaffolding, and exosomal functions are coordinated—and how its multiple PTMs (phosphorylation, succinylation) and transcriptional inputs (NF-κB, KLF6, miRNAs) are integrated—remains to be established.
  • No high-resolution structure of TAGLN2 bound to actin or any partner exists
  • The relationship between cytoskeletal and signaling-scaffold functions is mechanistically unexplained
  • In vivo genetic models for most cancer-associated TAGLN2 axes are lacking

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 4 GO:0098772 molecular function regulator activity 3
Localization
GO:0005856 cytoskeleton 3 GO:0005829 cytosol 2 GO:0005886 plasma membrane 2
Pathway
R-HSA-162582 Signal Transduction 4 R-HSA-168256 Immune System 3
Partners
ACTA1ANXA2ARPC5CFL1ERK1ERK2TMSB4XYBX1

Evidence

Reading pass · 22 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 TAGLN2 stabilizes cortical F-actin at the immunological synapse (IS) by competing with cofilin to block actin depolymerization, both in vitro and in vivo. TAGLN2 knockout reduced F-actin content, destabilized F-actin ring formation, decreased cell adhesion/spreading, and weakened cytokine production and cytotoxic effector function in T cells. TAGLN2 also enables LFA-1 activation following TCR stimulation. TAGLN2 knockout mice (TAGLN2-/-), in vitro actin depolymerization competition assays, live imaging, F-actin content measurement, cytokine/granzyme B assays The Journal of cell biology High 25869671
2018 TAGLN2 nucleates G-actin polymerization under low ionic/salt conditions via its calponin homology domain and actin-binding loop, which mechanically connect two adjacent G-actins enabling multimeric interactions. Under physiological salt conditions, TAGLN2 blocks Arp2/3 complex binding to actin filaments, thereby inhibiting branched actin nucleation. In HeLa and T cells, TAGLN2 enhances filopodium-like membrane protrusion. In vitro actin polymerization assays under varying ionic conditions, domain mutagenesis (calponin homology domain and actin-binding loop), Arp2/3 complex binding assays, live cell imaging of filopodia Scientific reports High 29615809
2011 PFTK1 kinase phosphorylates TAGLN2 at serine residues S83 and S163, reducing TAGLN2's actin-binding affinity. Unphosphorylated TAGLN2 strongly binds actin and suppresses actin cytoskeleton dynamics and HCC cell motility. Knockdown of TAGLN2 in PFTK1-suppressed cells overrides the inhibitory effect on invasion/motility, placing TAGLN2 downstream of PFTK1 in an oncogene-tumor suppressor interplay. 2D-PAGE mass spectrometry to identify phosphorylated substrates, site-directed mutagenesis of S83 and S163, actin binding assays, cell invasion/motility assays, genetic epistasis (double knockdown) Oncogene High 21577206
2017 TAGLN2 is required for phagocytosis in LPS-activated macrophages. TAGLN2 is induced by LPS via the NF-κB pathway. TAGLN2-deficient macrophages show defective phagocytosis of IgM- and IgG-coated sheep red blood cells and bacteria, with down-regulated PI3K/AKT and Ras-ERK signaling. TAGLN2-/- mice show higher mortality after bacterial infection. TAGLN2 knockout mice (TAGLN2-/-), phagocytosis assays (IgM/IgG-coated RBCs, bacteria), NF-κB pathway inhibition, in vivo bacterial infection survival Scientific reports High 28821818
2018 TAGLN2 is physically associated with LFA-1 and potentiates inside-out costimulation via LFA-1, enhancing immunological synapse formation between cytotoxic T cells and tumor cells. Recombinant TAGLN2 fused with a protein transduction domain (TG2P) enhanced CAR-T cell killing of Raji B-lymphoma cells and reduced tumor growth in mice. Co-localization/association studies, OTI TCR CD8+ T cell killing assays, recombinant protein transduction, xenograft mouse model, CAR-T cell assay Oncoimmunology Medium 30524895
2011 TAGLN2 is a direct transcriptional target of miR-1 and miR-133a; both miRNAs bind the 3'-UTR of TAGLN2 mRNA and suppress its expression. Silencing of TAGLN2 inhibits bladder cancer cell proliferation and increases apoptosis. miRNA expression signature, luciferase reporter assay (3'-UTR), TAGLN2 siRNA knockdown, proliferation/apoptosis assays British journal of cancer Medium 21304530
2011 TAGLN2 is a direct target of miR-1 in head and neck squamous cell carcinoma; miR-1 binds the TAGLN2 3'-UTR to suppress expression, and TAGLN2 silencing inhibits cell proliferation and invasion. miRNA target prediction, luciferase reporter assay, TAGLN2 siRNA knockdown, proliferation/invasion assays Oncotarget Medium 21378409
2014 miR-133a directly binds the 3'-UTR of TAGLN2 mRNA and suppresses TAGLN2 at both transcriptional and translational levels. TAGLN2 knockout attenuates hypoxia-induced apoptosis in cardiomyocytes via modulation of the caspase-8 apoptotic pathway. Dual-luciferase reporter assay (3'-UTR of TAGLN2), TAGLN2 knockdown, caspase activity assays, Bcl-2/caspase western blots in H9c2 cells under hypoxia Molecular and cellular biochemistry Medium 25421410
2022 TAGLN2 binds directly to E-cadherin (confirmed by Co-IP and microscale thermophoresis). Reduced TAGLN2 expression decreases cleavage of the E-cadherin extracellular domain, impairing trophoblast migration, invasion, and fusion. In vivo, adenoviral overexpression of TAGLN2 in pregnant mice induced a PE-like syndrome with hypertension. Co-immunoprecipitation, microscale thermophoresis, TAGLN2 knockdown functional assays (migration, invasion, fusion), mouse adenoviral injection model Frontiers in cell and developmental biology Medium 35281112
2022 TAGLN2 is succinylated at lysine-40 (K40) in glioma endothelial cells. A succinylation-mimetic mutant (K40E) promotes angiogenesis, actin cytoskeleton remodeling, and VE-cadherin expression in vitro and in vivo. TAGLN2 interacts with TMSB4X; K40 succinylation is required for this interaction (TAGLN2K40A abolishes binding). TMSB4X inhibition attenuates TAGLN2 K40succ-induced glioma proliferation and migration. TMT labeling, LC-MS/MS succinylation proteomics, succinylation-mimetic (K40E) and loss (K40R/K40A) mutagenesis, in vitro angiogenesis assays, xenograft model, immunofluorescence co-localization of TMSB4X-TAGLN2 Cancer gene therapy Medium 36131066
2024 TAGLN2 interacts with ERK1/2 (confirmed by Co-IP and LC-MS/MS). TAGLN2 knockdown decreases nuclear p-ERK1/2 and MGMT expression, increasing TMZ sensitivity in GBM. TAGLN2 overexpression increases p-ERK1/2 in the nucleus and MGMT levels, conferring TMZ resistance. NF-κB transcriptionally regulates TAGLN2 expression (validated by ChIP-PCR). Co-immunoprecipitation, LC-MS/MS, TAGLN2 KD/OE in GBM cells, western blot for p-ERK1/2/MGMT, intracranial xenograft, ChIP-PCR for NF-κB at TAGLN2 promoter Cancer letters Medium 38992489
2021 TAGLN2 promotes colorectal cancer cell proliferation, invasion, migration and EMT by activating STAT3 phosphorylation through ANXA2. TAGLN2 knockdown suppresses STAT3 phosphorylation, and the effects of TAGLN2 overexpression are reversed by STAT3 inhibitors. ANXA2 expression is positively associated with STAT3. TAGLN2 shRNA knockdown and overexpression in CRC cells, STAT3 inhibitor rescue experiments, western blot for p-STAT3/EMT markers, proliferation/migration/invasion assays Oncology letters Medium 34466149
2016 TAGLN2 positively regulates HBV transcription and replication in vitro: ectopic TAGLN2 expression enhances HBV transcription and replication, while TAGLN2 knockdown has the contrary effect. HBx protein induces TAGLN2 expression in a dose-dependent manner. Ectopic TAGLN2 expression and knockdown in HepG2 and HepG2.2.15 cells, Tet-on HBx cell line for dose-dependent induction, qRT-PCR for HBV transcripts Biochemical and biophysical research communications Medium 27402267
2021 In zebrafish, tagln2 is a direct downstream target of the transcription factor klf6a in caudal vein pruning. The klf6a-tagln2 axis regulates endothelial cell rearrangement (nucleus migration, junction remodeling) and actin cytoskeleton dynamics during vessel pruning driven by blood flow. Zebrafish transgenic models, klf6a loss-of-function, tagln2 rescue experiments, live imaging of EC rearrangement and actin dynamics PLoS genetics Medium 34319989
2024 TAGLN2 upregulates resistance-signature interferon-stimulated genes (ISGs) by enhancing YBX1-associated ssDNA aggregation and cGAS-STING pathway activation. TAGLN2 modulates YBX1 by recruiting c-Myc and SOX9 to the YBX1 promoter and by directly interacting with AKT-YBX1, enhancing YBX1 phosphorylation and nuclear translocation. Fisetin or MK2206 disrupts the TAGLN2-YBX1-AKT interaction and reduces ISG upregulation and therapy resistance. Co-IP for TAGLN2-AKT-YBX1 interaction, ChIP for c-Myc/SOX9 at YBX1 promoter, cGAS-STING pathway assays, ssDNA aggregation assays, pharmacological inhibitors (Fisetin, MK2206), xenograft models Cell death & disease Medium 39168971
2024 TAGLN2 directly binds ARPC5 (confirmed by Co-IP), positively regulating ARPC5 expression and activating the MEK/ERK signaling pathway to promote pancreatic cancer cell proliferation, invasion, and metastasis. Silencing ARPC5 reverses the pro-tumorigenic effects of TAGLN2 overexpression. Co-immunoprecipitation, immunofluorescence, TAGLN2 KD/OE in PANC-1 and SW1990 cells, ARPC5 knockdown rescue, MEK inhibitor (U0126), in vivo xenograft Cellular signalling Medium 38744388
2025 TAGLN2 promotes the ANXA2/NF-κB axis activation in Kupffer cells, contributing to inflammatory cytokine production and hepatocyte pyroptosis in acute pancreatitis-induced liver injury. TAGLN2 knockout reduces pyroptosis-related protein expression and liver dysfunction markers. TAGLN2 knockout mice, cerulein AP model, LPS-stimulated Kupffer cells in vitro, western blot for ANXA2/NF-κB/pyroptosis proteins, inflammatory cytokine measurement Archivum immunologiae et therapiae experimentalis Medium 40472315
2022 TAGLN2 promotes papillary thyroid carcinoma invasion via the Rap1/PI3K/AKT signaling pathway. Quantitative proteomics and gene expression profiling identified ITGB5, LAMC2, CRKL, and EMT markers as downstream molecules. Rescue experiments validated Rap1/PI3K/AKT pathway involvement in TAGLN2-mediated invasion. TAGLN2 KD/OE in PTC cell lines, gene expression profiling, quantitative proteomics, western blot for Rap1/PI3K/AKT, rescue experiments with pathway inhibitors, invasion/migration assays Endocrine-related cancer Medium 36222755
2025 CXCR7 physically interacts with TAGLN2 in PTC cells (confirmed by Co-IP and immunofluorescence co-localization). TAGLN2 knockdown reduces p-Smad2 levels (suppressing TGF-β/Smad2 signaling), and CXCR7 re-introduction into TAGLN2-silenced cells restores p-Smad2 levels, indicating CXCR7 promotes PTC invasion/metastasis through TAGLN2 via TGF-β/Smad2 signaling. Co-immunoprecipitation, immunofluorescence colocalization, TAGLN2 knockdown/CXCR7 overexpression, western blot for p-Smad2 Frontiers in immunology Medium 41169389
2026 Tumor-derived exosomal TAGLN2 delivered to endothelial cells transcriptionally upregulates NRP1 via c-Jun/SP1, induces SEMA4D expression, and forms a stable cytoplasmic ternary complex with NRP1 and SEMA4D that activates YAP by disrupting NRP1-YAP cytoplasmic retention and suppressing Hippo-mediated YAP degradation, independently of the canonical SEMA4D-PlexinB1-RhoA/ROCK pathway, thereby promoting angiogenesis, EndoMT, vascular permeability, and gastric cancer metastasis. Exosome isolation and delivery assays, Co-IP for ternary complex, ChIP for c-Jun/SP1 at NRP1 promoter, YAP localization assays, in vivo tumor xenograft, mechanistic rescue with pathway inhibitors Advanced science Medium 41824788
2018 miR-145-5p directly targets TAGLN2 (validated by luciferase assay); high TAGLN2 expression promotes bladder cancer cell proliferation and migration. Luciferase reporter assay (3'-UTR), miR-145-5p overexpression, TAGLN2 knockdown, proliferation/migration assays Oncology letters Low 30405771
2022 TAGLN2 co-localizes with F-actin in ovarian cancer cells; TAGLN2 knockdown impairs cytoskeletal organization and reduces cell proliferation and migration. Immunofluorescence for F-actin co-localization, siRNA knockdown, colony formation, wound healing assays Applied immunohistochemistry & molecular morphology Low 40247723

Source papers

Stage 0 corpus · 50 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 The tumour-suppressive function of miR-1 and miR-133a targeting TAGLN2 in bladder cancer. British journal of cancer 246 21304530
2011 miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 154 21378409
1995 Prediction of the coding sequences of unidentified human genes. III. The coding sequences of 40 new genes (KIAA0081-KIAA0120) deduced by analysis of cDNA clones from human cell line KG-1. DNA research : an international journal for rapid publication of reports on genes and genomes 92 7788527
2015 TAGLN2 regulates T cell activation by stabilizing the actin cytoskeleton at the immunological synapse. The Journal of cell biology 81 25869671
2011 A novel interplay between oncogenic PFTK1 protein kinase and tumor suppressor TAGLN2 in the control of liver cancer cell motility. Oncogene 77 21577206
2018 miR-145-5p inhibits the proliferation and migration of bladder cancer cells by targeting TAGLN2. Oncology letters 65 30405771
2016 The tumor-suppressive function of miR-1 by targeting LASP1 and TAGLN2 in esophageal squamous cell carcinoma. Journal of gastroenterology and hepatology 57 26414725
2014 miR-133a mediates the hypoxia-induced apoptosis by inhibiting TAGLN2 expression in cardiac myocytes. Molecular and cellular biochemistry 48 25421410
2017 An Essential Role for TAGLN2 in Phagocytosis of Lipopolysaccharide-activated Macrophages. Scientific reports 40 28821818
2014 MiR-133b regulates the expression of the Actin protein TAGLN2 during oocyte growth and maturation: a potential target for infertility therapy. PloS one 37 24959893
2021 MicroRNA‑133b alleviates doxorubicin‑induced cardiomyocyte apoptosis and cardiac fibrosis by targeting PTBP1 and TAGLN2. International journal of molecular medicine 32 33982775
2021 TAGLN2 promotes the proliferation, invasion, migration and epithelial-mesenchymal transition of colorectal cancer cells by activating STAT3 signaling through ANXA2. Oncology letters 30 34466149
2018 MicroRNA-133b suppresses bladder cancer malignancy by targeting TAGLN2-mediated cell cycle. Journal of cellular physiology 24 30317571
2018 TAGLN2 polymerizes G-actin in a low ionic state but blocks Arp2/3-nucleated actin branching in physiological conditions. Scientific reports 23 29615809
2022 Salvianolic acid A (Sal A) suppresses malignant progression of glioma and enhances temozolomide (TMZ) sensitivity via repressing transgelin-2 (TAGLN2) mediated phosphatidylinositol-3-kinase (PI3K) / protein kinase B (Akt) pathway. Bioengineered 19 35505656
2015 TAGLN2-mediated actin stabilization at the immunological synapse: implication for cytotoxic T cell control of target cells. BMB reports 19 26129675
2022 Lysine-40 succinylation of TAGLN2 induces glioma angiogenesis and tumor growth through regulating TMSB4X. Cancer gene therapy 18 36131066
2021 Quercetin Antagonizes Esophagus Cancer by Modulating miR-1-3p/TAGLN2 Pathway-Dependent Growth and Metastasis. Nutrition and cancer 17 34498538
2021 An Essential NRP1-Mediated Role for Tagln2 in Gastric Cancer Angiogenesis. Frontiers in oncology 16 34150622
2021 miR-133a-3p regulates the proliferation and apoptosis of intestinal epithelial cells by modulating the expression of TAGLN2. Experimental and therapeutic medicine 15 34149870
2024 Unveiling the role of TAGLN2 in glioblastoma: From proneural-mesenchymal transition to Temozolomide resistance. Cancer letters 14 38992489
2022 TAGLN2-Regulated Trophoblast Migration, Invasion and Fusion are Impaired in Preeclampsia. Frontiers in cell and developmental biology 14 35281112
2021 MiR-613 inhibits the proliferation, migration, and invasion of papillary thyroid carcinoma cells by directly targeting TAGLN2. Cancer cell international 14 34530821
2024 TAGLN2 induces resistance signature ISGs by activating AKT-YBX1 signal with dual pathways and mediates the IFN-related DNA damage resistance in gastric cancer. Cell death & disease 13 39168971
2022 TAGLN2 promotes papillary thyroid carcinoma invasion via the Rap1/PI3K/AKT axis. Endocrine-related cancer 13 36222755
2021 The blood flow-klf6a-tagln2 axis drives vessel pruning in zebrafish by regulating endothelial cell rearrangement and actin cytoskeleton dynamics. PLoS genetics 13 34319989
2018 Actin stabilizer TAGLN2 potentiates adoptive T cell therapy by boosting the inside-out costimulation via lymphocyte function-associated antigen-1. Oncoimmunology 13 30524895
2023 CircRNA ZKSCAN1 promotes lung adenocarcinoma progression by miR-185-5p/TAGLN2 axis. Thoracic cancer 12 37105934
2022 Comparative proteomics identify HSP90A, STIP1 and TAGLN-2 in serum extracellular vesicles as potential circulating biomarkers for human adenomyosis. Experimental and therapeutic medicine 11 35495589
2018 Effect of TAGLN2 in the regulation of meningioma tumorigenesis and development. European review for medical and pharmacological sciences 10 29424888
2022 TAGLN2 Promotes the Proliferation, Migration, Invasion, and EMT of Clear Cell Renal Cell Carcinoma Through the PI3K/Akt Signaling Pathway. Biochemical genetics 9 36547768
2023 Single-cell RNA sequencing reveals the lineage of malignant epithelial cells and upregulation of TAGLN2 promotes peritoneal metastasis in gastric cancer. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 8 37247132
2016 TAGLN2, a novel regulator involved in Hepatitis B virus transcription and replication. Biochemical and biophysical research communications 8 27402267
2024 Circular STAG2 RNA Modulates Bladder Cancer Progression via miR-145-5p/TAGLN2 and Is Considered as a Biomarker for Recurrence. Cancers 7 38473339
2019 [MicroRNA-133b suppresses cell proliferation and invasion of esophageal squamous cell carcinoma via downregulating TAGLN2 expression]. Zhonghua zhong liu za zhi [Chinese journal of oncology] 7 30862136
2021 miR-133b targets tagln2 and functions in tilapia oogenesis. Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 5 34147671
2024 TAGLN2 targeted control of ARPC5-mediated activation of the MEK/ERK signaling pathway influences the proliferation, invasion, and metastasis of pancreatic cancer cells. Cellular signalling 4 38744388
2024 Down-regulation of TAGLN2 associated with the development of preeclampsia by effecting the Rap1 signaling pathway. Placenta 4 39602835
2025 TAGLN2 Exacerbates Acute Pancreatitis-Induced Liver Injury by Increasing Hepatocyte Pyroptosis via Kupffer Cells-Mediated Inflammatory Response. Archivum immunologiae et therapiae experimentalis 3 40472315
2025 TAGLN2-mediated Actin Cytoskeleton Stabilization Promotes Proliferation and Metastasis of Ovarian Carcinoma. Applied immunohistochemistry & molecular morphology : AIMM 2 40247723
2024 Metformin Radiosensitizing Effect on Hypoxic Oral Squamous Cell Carcinoma Cells by GAPDH and TAGLN2. Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2 39160673
2020 Retracted Article: Overexpression of circ_0034642 contributes to hypoxia-induced glycolysis, cell proliferation, migration and invasion in gliomas by facilitating TAGLN2 expression via sponging miR-625-5p. RSC advances 2 35494452
2025 Decoding TAGLN2 in cancer: the molecular linchpin bridging actin remodeling, immune dysregulation and therapeutic challenges. International journal of biological macromolecules 1 40675291
2025 Isoliquiritigenin inhibits the activation of the ANXA2/STAT3 pathway by down-regulating TAGLN2, thereby alleviating alcoholic fatty liver. Biochemical pharmacology 1 40921221
2025 CXCR7-TAGLN2 protein complex regulates invasion and metastasis in papillary thyroid carcinoma: a potential therapeutic target. Frontiers in immunology 1 41169389
2021 Retraction: Overexpression of circ_0034642 contributes to hypoxia-induced glycolysis, cell proliferation, migration and invasion in gliomas by facilitating TAGLN2 expression via sponging miR-625-5p. RSC advances 1 35427031
2026 Hsa_circ_PCNT sponges hsa-miR-133b to promote SHH medulloblastoma via TAGLN2. Cellular and molecular life sciences : CMLS 0 41483179
2026 Tumor-Derived Exosomal TAGLN2 Promotes Metastasis by Inducing Vascular Permeability and Angiogenesis via the NRP1/SEMA4D/YAP Axis. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 0 41824788
2025 Exploration of upstream and downstream mechanisms of the TAGLN2 gene in pulmonary arterial hypertension. Medicine 0 41189171
2025 Integrating Magnetic Bead-Based SELEX with In Silico Binding Analyses for the Identification of High-Affinity DNA Aptamers Targeting TAGLN2. ACS omega 0 41358073